Reason you will be REJECTED BY THE FDA simple explanation:
First of all, I expect a dead stock .. @ .15 cents to .20 cents let me say that. idiots will take it up when its "oversold"..
but i also know you cant get FDA approval and here is why...
The FDA is going to ask you for evidence of SAFETY AND EFFECTIVENESS ..
they vote on both of those issues...
this drug has ZERO EVIDENCE of both its safety and effectiveness.
the drug was tried by 31 people with A SINGLE DOSE and they were taken off of the drug right after the SINGLE DOSE.
no evidence of anything at all.. in fact it appears you are hiding something to take them off that fast..
also , the "company" has ZERO EMPLOYEES AND A HORRIBLE TRACK RECORD..
NO WAY IN HE11 THIS HAS EVEN A 1% CHANCE OF APPROVAL
Sentiment: Strong Sell
RISKS RELATED TO OUR BUSINESS
Risks Related to Our Capital Requirements, Finances and Operations
We have incurred losses since our inception, we expect our operating expenses to continue to exceed our revenue for the foreseeable future, and we may never generate revenue sufficient to achieve profitability.
We are a development-stage company and have not generated sustainable revenue from operations or been profitable since inception, and we may never achieve profitability. We have devoted our resources to acquiring and developing proprietary product candidates, but such product candidates cannot be marketed until the regulatory process is completed and governmental approvals have been obtained. We have accumulated net losses totaling approximately $192.8 million as of March 31, 2013, and we expect to continue to incur substantial operating losses for the next several years as we advance MST-188, our lead product candidate, through clinical studies and other development activities and seek approval from the FDA to commercialize it. Accordingly, there is no current source of revenue from operations, much less profits, to sustain our present activities. Further, no revenue from operations will likely be available until, and unless, we enter into an arrangement that provides for licensing revenue or other partnering-related funding or MST-188 or another product candidate is approved by the FDA or another regulatory agency, and successfully marketed, outcomes which we may not achieve.
The success of our business currently is dependent on the success of MST-188 and this product candidate may not receive regulatory approval or be successfully commercialized.
We currently have no products for sale and we are focusing our resources almost exclusively on the development of MST-188. Accordingly, the success of our business currently depends on our ability, or that of a future partner, to successfully develop.Without that dilution of the company may .....
Sentiment: Strong Sell
If what you say is true, then why are two analysts predicting a PPS between $1.50 and $2.00, within the next 12 months? What are they seeing in this stock that you are not seeing?